...t has become evident that familial atypical HUS is strongly associated with mutations in proteins needed either for activation or regulation of the alternative pathway of Complement. For this reason, ADIENNE S.r.l. (Italy) has obtained orphan designation EU/3/08/571 for its Recombinant human minibody against Complement component C5 for the treatment of atypical Haemolytic Uraemic Syndrome (aHUS) a ...